• A
  • |
  • A
  • Text size
A Brief Guide to Pharmacogenetics and Pain Management
September 25, 2013

This webinar will examine the genetic basis for differences in clinical responses observed among patients receiving opioid analgesics. Mutations in genes encoding the mu opioid receptor have been linked to the variability in responses to opioids. Other genetic polymorphisms affect the bioavailability and metabolic disposition of opioids and their metabolites. Pharmacogenetic studies also have provided a molecular foundation supporting opioid rotation in cases where efficacy diminishes or intolerable side effects occur. As genetic findings on specific opioid analgesics are extended, clinicians will be better positioned to identify from the outset which opioid analgesic may be most appropriate for an individual patient.

Learning objectives

  • Explain the genetic foundation and clinical importance of single nucleotide polymorphisms (SNPs)
  • Discuss SNPs that are clinically important determinants of patient variability to opioid analgesics and their implications for opioid rotation practices
  • Explain how pharmacogenetic findings may ultimately inform clinical decision-making in pain management


Charles E. Argoff, M.D.
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center

The content of this activity does not relate to any product of a commercial interest.

The duration of this webinar is 60 minutes 

Add To Cart
Select a Session Format:
Online Archive ($0.00 for Member/Non-Member)